International Vaccine Institute
80% goes to programs $0 to raise $100 Strong reserves Growing revenue
International Vaccine Institute is a 501(c)(3) organization, registered in 1999, with $68,966,984 in FY2024 revenue. CharityIndex grades it A, and it directs about 80% of spending to programs.
Seoul 08826, Republic of Korea, 00000 EIN 31-1621592 Since 1999
Revenue (FY2024)
$69.0M
▼ 28.6% vs prior year
International median: $227K
Expenses (FY2024)
$74.3M
Net assets
$94.6M
Employees
260
CharityIndex rating
One independent A+ to F grade from four published criteria, each scored separately from IRS filings and combined by weight.
A
AProgram efficiency40% of the rating80% to programs · $0 to raise $100
Measures how much of every dollar spent actually reaches programs, plus what it costs to raise $100 of donations. The worse of the two measures sets the letter (85%+ to programs is an A; under $15 to raise $100 is an A), averaged over the three most recent filings. For International Vaccine Institute: 80% to programs · $0 to raise $100 earns a A on this criterion. See the exact thresholds →
B+Financial health25% of the rating15 mo reserves · -8% margin
Measures whether the organization is built to last: how many months its reserves would cover expenses (3+ months earns an A-range score, but hoarding 5+ years of budget is capped) and whether it runs a surplus or a deficit. For International Vaccine Institute: 15 mo reserves · -8% margin earns a B+ on this criterion. See the exact thresholds →
A+Governance25% of the rating6 of 6 checks met
Checks how the organization is run, from its own Form 990: an independent board majority, a board of five or more, conflict-of-interest, whistleblower and document-retention policies, and independently audited financials. The share of disclosed checks that pass sets the letter. For International Vaccine Institute: 6 of 6 checks met earns a A+ on this criterion. See the exact thresholds →
A+Transparency10% of the rating5 of 5 disclosure signals
Counts five disclosure signals: a recent filing, a mission statement, program descriptions, a listed website, and the full expense breakdown. More disclosure, better letter. For International Vaccine Institute: 5 of 5 disclosure signals earns a A+ on this criterion. See the exact thresholds →
Show this grade on your website
A live seal — it updates automatically when the grade changes and links donors to this verified profile.
Mission
To discover, develop and deliver safe, effective and affordable vaccines for global public health. its vision is developing countries free of suffering from infectious disease.
What they do
Bpcov2 project - 2024 summary of activities (reference year 2024) in 2024, the bpcov2 project advanced pre-clinical development of a next-generation pan-coronavirus mrna vaccine platform supported by cepi. project partners (upenn, unc, uc davis, chula vrc, and ivi) focused on mrna construct design and production. multiple mrna constructs were produced and tested, including spike variants, chimeric constructs, and vlp platforms, formulated with sm-102 to enable platform comparison.
Vat0008 is a pivotal multi-country phase 3, multi-stage, modified double-blind and multi-arm study where efficacy, safety and immunogenicity of two sars-cov-2 adjuvanted recombinant protein vaccines (monovalent and bivalent) were tested as primary series and monovalent booster dose as an extension. ivi led the effort in nepal to conduct the clinical trial including conducting the local dsmb meeting. the primary series study was initiated in july 2021. the first subject for the primary series was enrolled in september 2021. the crossover/booster phase started in january 2023. the last subject vaccination for the crossover/booster phase was completed in november 2023. investigators meeting was conducted in february 2023 for the successful conduction of the primary series study. the 11th dsmb meeting was held on september 2023, and no safety concern was raised. ivi team conducted a quality control visit in q3 2023. final quality control visit to sites was done in q2 2024. study site close-out was activity was completed in q3 2024. study document archiving process was done in q3 2024. final database lock was done in q3 2024. final dsmb preparation was completed at the end of 2024, and meeting was conducted in january 2025. no safety concerns were raised.
Contact & location
- Address
- Seoul 08826, Republic of Korea, 00000
- City
- —
- State
- —
- Subcategory
- Alliances, Advocacy & Professional Societies
- Phone
- …
- Website
- …
Financial trends
Revenue grew from $19.7M (FY2013) to $69.0M (FY2024) across 12 reported years.
Financial snapshot
Financial health & position (FY2024)
Liabilities $7.0MNet assets $94.6M
Operating margin
-7.7%
Spent more than it raised in the latest fiscal year.
Total assets
$101.6M
Total liabilities
$7.0M
Net assets
$94.6M
Salaries & benefits
$22.8M
31% of expenses
Board members
20
19 independent
Financials by year
| Fiscal year | Revenue | Expenses | Net assets | Total assets | Form |
|---|---|---|---|---|---|
| 2024 | $68,966,984▼28.6% | $74,250,925▼4.4% | $94,592,624▼5.1% | $101,596,804▼3.0% | 990 |
| 2023 | $96,582,480▲26.8% | $77,682,016▲24.7% | $99,638,042▲23.6% | $104,790,256▲20.8% | 990 |
| 2022 | $76,157,886▲46.4% | $62,286,216▲23.4% | $80,623,108▲20.8% | $86,735,648▲21.1% | 990 |
| 2021 | $52,033,675▼3.4% | $50,489,753▲54.2% | $66,751,438▲2.4% | $71,611,847▲5.7% | 990 |
| 2020 | $53,885,143▲72.1% | $32,741,998▲18.0% | $65,207,516▲48.0% | $67,725,018▲46.0% | 990 |
| 2019 | $31,316,543▲3.5% | $27,746,077▼2.9% | $44,064,371▲424% | $46,388,925▲119% | 990 |
| 2018 | $30,266,811▲8.9% | $28,586,073▲10.2% | $8,410,785▲22.4% | $21,208,830▲1.4% | 990 |
| 2017 | $27,796,517▲6.7% | $25,942,177▲3.7% | $6,872,651▲39.0% | $20,916,339▼10.9% | 990 |
| 2016 | $26,056,902▲23.2% | $25,025,024▲14.6% | $4,945,995▲32.4% | $23,484,429▼18.1% | 990 |
| 2015 | $21,152,043▼10.4% | $21,829,246▼6.6% | $3,734,352▼23.7% | $28,657,279▼2.5% | 990 |
| 2014 | $23,603,261▲19.8% | $23,364,720▲10.1% | $4,892,493▼30.8% | $29,405,974▼22.6% | 990 |
| 2013 | $19,694,575 | $21,214,552▼5.4% | $7,068,199▼18.2% | $37,977,708▲7.4% | 990 |
| 2012 | — | $22,426,950▼11.6% | $8,640,549▼37.1% | $35,345,744▼8.1% | 990 |
| 2011 | — | $25,382,850▲8.6% | $13,732,183▲0.6% | $38,469,314▼17.3% | 990 |
| 2010 | — | $23,374,863 | $13,652,867 | $46,498,641 | 990 |
Original Form 990 PDFs (the Form column) are served by ProPublica Nonprofit Explorer, as filed with the IRS. Create a free account to download the CSV report.
Leadership & compensation (FY2024)
Highest-paid: Jerome Kim — $756,439 (1.02% of total expenses)
| Name | Title | Hours/week | Compensation |
|---|---|---|---|
| Jerome Kim | Director General | 40 | $756,439 |
| Francois Belin | Chief Operating Officer | 40 | $486,257 |
| Florian Marks | Deputy Director General, Epidemiology | 40 | $346,625 |
| Anh Wartel | Deputy Director, General, Europe | 40 | $338,690 |
| Hee Soo Kim | Deputy Director General, Clinical Assessment | 40 | $336,079 |
| John D Clemens | Senior Scientific Advisor | 40 | $323,736 |
| Manki Song | Deputy Director General, Science | 40 | $296,976 |
| Julia Lynch | Program Director, Cholera | 40 | $295,940 |
| Vincent Canouet | Deputy Director General, Strategy | 40 | $293,707 |
| Tobin Guarnacci | Global Head, Quality Management | 40 | $292,070 |
| Sushant Sahastrabuddhe | Associate Director General | 40 | $262,350 |
| Birkneh Tilahun Tadesse | Associate Director General Epidemiology | 40 | $252,958 |
| Kyung-taik Han | Deputy Director General, Government Relations | 40 | $237,717 |
| Douglas N Shaffer | Deputy Director General, Global Affairs | 40 | $126,739 |
| Jessica Cowden | Deputy Director General, Clinical, Assessment | 40 | $123,358 |
| Anthony Ford-hutchinson | Director / Board of Trustee | 1 | $1,500 |
| Christian W Mandl | Director / Board of Trustee | 1 | $1,500 |
| George Bickerstaff | Chairperson / Board of Trustee | 1 | $1,500 |
| Gordon Dougan | Director / Board of Trustee | 1 | $1,500 |
| Hannah Nohynek | Vice-chairperson/board Trustee | 1 | $1,500 |
Top vendors & contractors (FY2018)
| Contractor | Services | Paid |
|---|---|---|
| The Boston Consulting Group Inc | Consulting | $490,011 |
Grants received · $2.1M total
10 grants to International Vaccine Institute totaling $2.1M, reported by foundations on their Schedule I filings.
| Grantmaker | Purpose | Year | Amount |
|---|---|---|---|
| International Vaccine Institute | — | 2023 | $27,793 |
| International Vaccine Institute | Program service | 2022 | $291,514 |
| International Vaccine Institute | Program service | 2021 | $478,436 |
| International Vaccine Institute | Program service | 2020 | $188,771 |
| International Vaccine Institute | Program service | 2020 | $87,113 |
| International Vaccine Institute | Program service | 2019 | $557,960 |
| International Vaccine Institute | Program service | 2019 | $410,694 |
| International Vaccine Institute | Program service | 2019 | $47,295 |
| International Vaccine Institute | Program service | 2019 | $11,760 |
| International Vaccine Institute | Program service | 2019 | $9,635 |
Grants made · $3.5M in FY2024
13 grants totaling $3.5M in FY2024. All grants made by International Vaccine Institute →
| Recipient | Purpose | Amount |
|---|---|---|
| Icon Gov't & Public Health Solutions | Program service | $1,543,955 |
| University of North Carolina At Chapel Hill | Program service | $313,078 |
| Trustees of the University of Pennsylvania | Program service | $301,290 |
| Texas Tech University Health Science | Program service | $285,000 |
| Regents of the University of California | Program service | $197,070 |
| Edjen Biotech LLC | Program service | $165,000 |
| Mass General Brigham Incorporated | Program service | $161,049 |
| Johns Hopkins University | Program service | $150,000 |
| President and Fellows of Harvard College | Program service | $139,555 |
| Professional Nurses Chapter of the Brigham & Womens Hospital | Program service | $125,334 |
| New York University | Program service | $78,355 |
| University of Washington | Program service | $40,000 |
| University of Maryland | Program service | $39,960 |
Frequently asked questions
- Is International Vaccine Institute a legitimate nonprofit?
- Yes. International Vaccine Institute is a 501(c)(3) organization registered with the U.S. Internal Revenue Service under EIN 31-1621592.
- What is International Vaccine Institute's EIN?
- International Vaccine Institute's Employer Identification Number (EIN) is 31-1621592.
- How much revenue does International Vaccine Institute report?
- International Vaccine Institute reported $68,966,984 in total revenue on its fiscal year 2024 IRS Form 990 filing.
- How much of International Vaccine Institute's spending goes to programs?
- International Vaccine Institute spends about 80% of its total expenses on programs, based on its latest IRS Form 990.
- What financial grade does International Vaccine Institute have?
- CharityIndex grades International Vaccine Institute A, based on program efficiency and fundraising cost.
- How much does International Vaccine Institute's highest-paid employee make?
- The highest reported compensation on International Vaccine Institute's latest Form 990 is $756,439, paid to Jerome Kim (Director General).
Explore more
Data for International Vaccine Institute (EIN 31-1621592) comes from the IRS Business Master File and e-filed Form 990 returns, via CharityIndex. Figures reflect what the organization reported to the IRS for each fiscal year.